Cochrane · systematic review · CD009684
Zonisamide for essential tremor
Bruno, E, Nicoletti, A, Filippini, G, et al. · Cochrane Database of Systematic Reviews · 2017 · Cochrane Library
Movement DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
3
current version
GRADE rated
3
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 3 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Zonisamide versus placebo for essential tremor
Population: participants with essential tremor
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Functional abilities Change in TRS part B score (motor tasks) Change in TRS part C score (functional disability) (higher scores indicate a better outcome) Zonisamide vs placebo | MD 0 | 1 study · 20 participants | Very low Downgraded: risk of bias, imprecision |
Study withdrawal for any reason Number of participants withdrawn from the study Zonisamide vs placebo | RD 0.1 | 1 study · 20 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events Number of adverse events Zonisamide vs placebo | RD 0.6 [0.28, 0.92] | 1 study · 20 participants | Very low Downgraded: risk of bias, imprecision |